Jason Haddock, Array BioPharma Inc. (ARRY)’s insider Unloaded 7,500 Shares; Convergence Investment Partners Cut Digital Rlty Tr (DLR) Position

January 16, 2018 - By Richard Conner

The CFO of Array Biopharma Inc, Jason Haddock has made a surprising deal in the Pinksheet-listed Array Biopharma Inc that is worth $102,975 U.S Dollars. As disclosed in the U.S. SEC public document filed on 16/01/2018, Jason sold 7,500 shares calculated with average price per share of $13.7. Jason Haddock presently owns 28,868 shares which make up precisely 0.01% of the Colorado-Company’s total market cap.

Convergence Investment Partners Llc decreased Digital Rlty Tr Inc (DLR) stake by 41.88% reported in 2017Q3 SEC filing. Convergence Investment Partners Llc sold 2,590 shares as Digital Rlty Tr Inc (DLR)’s stock rose 10.26%. The Convergence Investment Partners Llc holds 3,595 shares with $425,000 value, down from 6,185 last quarter. Digital Rlty Tr Inc now has $22.97B valuation. The stock increased 1.61% or $1.7 during the last trading session, reaching $107.48. About 1.89 million shares traded or 52.92% up from the average. Digital Realty Trust, Inc. (NYSE:DLR) has risen 23.90% since January 16, 2017 and is uptrending. It has outperformed by 7.20% the S&P500.

Among 20 analysts covering Digital Realty Trust (NYSE:DLR), 10 have Buy rating, 1 Sell and 9 Hold. Therefore 50% are positive. Digital Realty Trust had 74 analyst reports since July 31, 2015 according to SRatingsIntel. Jefferies maintained it with “Hold” rating and $119.0 target in Monday, October 16 report. On Wednesday, January 10 the stock rating was upgraded by Deutsche Bank to “Buy”. Macquarie Research maintained the stock with “” rating in Thursday, September 3 report. KeyBanc Capital Markets maintained the shares of DLR in report on Monday, December 14 with “Overweight” rating. The firm earned “Hold” rating on Monday, March 21 by Stifel Nicolaus. The firm has “Outperform” rating by Cowen & Co given on Monday, June 12. The company was upgraded on Friday, December 22 by Wells Fargo. The firm earned “Outperform” rating on Wednesday, October 4 by RBC Capital Markets. The firm has “Buy” rating given on Tuesday, October 20 by Stifel Nicolaus. The stock of Digital Realty Trust, Inc. (NYSE:DLR) earned “Buy” rating by Jefferies on Tuesday, January 12.

Since August 16, 2017, it had 0 insider purchases, and 1 insider sale for $3.00 million activity. Sharp Christopher sold $3.00M worth of stock.

Investors sentiment increased to 2.06 in Q3 2017. Its up 1.03, from 1.03 in 2017Q2. It improved, as 44 investors sold DLR shares while 119 reduced holdings. 95 funds opened positions while 241 raised stakes. 198.28 million shares or 22.83% more from 161.43 million shares in 2017Q2 were reported. Kames Cap Plc holds 0.06% in Digital Realty Trust, Inc. (NYSE:DLR) or 17,298 shares. Old Mutual Customised Solutions (Proprietary) has 1,770 shares. Parkside Natl Bank has invested 0% in Digital Realty Trust, Inc. (NYSE:DLR). Amica Mutual Ins holds 7,686 shares. Cleararc Cap invested in 1.03% or 57,906 shares. Sg Americas Limited Co invested 0.01% in Digital Realty Trust, Inc. (NYSE:DLR). Security Trust holds 0.2% or 5,010 shares. Pennsylvania Tru stated it has 0.05% in Digital Realty Trust, Inc. (NYSE:DLR). Susquehanna Intl Llp holds 0% or 26,858 shares. Zeke Cap Advisors Lc holds 0.06% or 3,868 shares in its portfolio. 13,957 are held by Cambridge Inv Rech Advisors. Amer National Ins Commerce Tx stated it has 0.14% in Digital Realty Trust, Inc. (NYSE:DLR). Summit Securities Group Ltd owns 1,800 shares. Ccm Investment Advisers Limited Liability Corp owns 49,873 shares or 1.14% of their US portfolio. Moreover, Franklin Resource Incorporated has 0.01% invested in Digital Realty Trust, Inc. (NYSE:DLR).

Analysts await Digital Realty Trust, Inc. (NYSE:DLR) to report earnings on February, 15. They expect $1.52 EPS, up 6.29% or $0.09 from last year’s $1.43 per share. DLR’s profit will be $324.80 million for 17.68 P/E if the $1.52 EPS becomes a reality. After $1.51 actual EPS reported by Digital Realty Trust, Inc. for the previous quarter, Wall Street now forecasts 0.66% EPS growth.

Convergence Investment Partners Llc increased Rpx Corp (NASDAQ:RPXC) stake by 51,833 shares to 100,719 valued at $1.34 million in 2017Q3. It also upped Harsco Corp (NYSE:HSC) stake by 49,825 shares and now owns 129,959 shares. Apple Inc (NASDAQ:AAPL) was raised too.

Since September 29, 2017, it had 0 insider buys, and 4 sales for $12.91 million activity. The insider Robbins Andrew R sold $3.03 million. On Saturday, December 16 Squarer Ron sold $8.90M worth of Array BioPharma Inc. (NASDAQ:ARRY) or 819,671 shares. VAN LUNSEN GIL J sold $493,510 worth of Array BioPharma Inc. (NASDAQ:ARRY) on Friday, September 29. On Friday, September 29 the insider LEFKOFF KYLE sold $478,428.

Among 10 analysts covering Array BioPharma (NASDAQ:ARRY), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Array BioPharma has $18.0 highest and $7 lowest target. $13.86’s average target is 6.86% above currents $12.97 stock price. Array BioPharma had 29 analyst reports since June 3, 2016 according to SRatingsIntel. The firm earned “Neutral” rating on Friday, February 3 by JP Morgan. The stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Buy” rating given on Thursday, July 13 by Jefferies. The firm has “Buy” rating given on Wednesday, May 31 by Piper Jaffray. On Monday, August 29 the stock rating was maintained by Jefferies with “Buy”. The firm has “Mkt Perform” rating given on Monday, January 30 by Leerink Swann. Piper Jaffray maintained it with “Buy” rating and $18.0 target in Tuesday, October 31 report. The company was maintained on Sunday, September 10 by Cowen & Co. The firm earned “Buy” rating on Friday, August 5 by Stifel Nicolaus. The rating was maintained by Piper Jaffray with “Buy” on Wednesday, November 29. The firm has “Buy” rating by Piper Jaffray given on Wednesday, September 20.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company has market cap of $2.56 billion. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. It currently has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

Analysts await Array BioPharma Inc. (NASDAQ:ARRY) to report earnings on February, 8. They expect $-0.24 EPS, down 71.43% or $0.10 from last year’s $-0.14 per share. After $-0.22 actual EPS reported by Array BioPharma Inc. for the previous quarter, Wall Street now forecasts 9.09% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.